Generic Sweden (STO:GENI) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr44.6m (up 2.6% from 2Q 2024).
- Net income: kr7.18m (up 34% from 2Q 2024).
- Profit margin: 16% (up from 12% in 2Q 2024). The increase in margin was primarily driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Generic Sweden Revenues Disappoint
Revenue missed analyst estimates by 4.1%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the IT industry in Sweden.
Performance of the Swedish IT industry.
The company's shares are down 4.7% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Generic Sweden that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:GENI
Generic Sweden
A technology company, provides messaging services for all applications.
Flawless balance sheet 6 star dividend payer.
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Adobe: A Probabilistic Case for Undervaluation

A Capital Allocation Favorite with Structural Importance

Good foundation, but now it's all about the next steps
Recently Updated Narratives

CSL Investment Thesis

Investment Analysis (May 2026)

Mouwasat Medical Services Will Achieve a 25% Profit Margin in Just 3 Years
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

